Alkem

{{ Form::open(['url' => '#', 'name' => 'validateForm', 'id' => 'validateForm', 'enctype' => 'multipart/form-data']) }} @csrf

Back

Clinical usage

What factors influence your decision to prescribe FDC of Empagliflozin Linagliptin? (Select all that apply) *

Efficacy in lowering HbA1c Cardiovascular benefits Weight loss effects Patient preference Less Side effects

What has been your observed efficacy of FDC of empagliflozin Linagliptin in reducing HbA1c in patients with T2DM? *

<0.5% 0.5-0.8% 0.8-1.2% >1.2%

What percentage of patients achieved HbA1c <7% after 12 weeks of treatment with empagliflozin/linagliptin combination therapy? *

Up to 30% 30-60% 60-90% >90%

How do you decide the dose of Empagliflozin of either 10 mg or 25 mg for respective patients along with 5 mg Linagliptin? (select all that apply) *

HbA1c levels Renal function Comorbidities like HF Age Weight and BMI Side effects and tolerability

What is the percentage split to use empagliflozin at the 10 mg/25 mg dose in your clinical practice along with Linagliptin 5 mg? *

25/75% 40/60% 50/50% 75/25%

Which patient population do you prescribe FDC of Empagliflozin Linagliptin to most frequently? *

T2DM with ASCVD T2DM with CKD Heart failure patients (HFrEF or HFpEF) Patients with obesity

At what eGFR do you typically initiate empagliflozin in CKD patients with diabetes? *

≥60 mL/min/1.73 m² 45-59 mL/min/1.73 m² 30-44 mL/min/1.73 m² <30 mL/min/1.73 m²

What is the average percentage weight loss you have observed in T2DM patients on FDC of empagliflozin Linagliptin? *

<2% 2-4% 5-7% >7%

What is your primary concern regarding FDC of empagliflozin Linagliptin use? *

Risk of genitourinary infections Cost of treatment Limited availability in certain regions Lack of long-term real-world evidence

What percentage of patients with FDC of Empagliflozin Linagliptin develop genitourinary infections? *

<5% 5-10% 10-20% >20%

@include('user.footer')